This $ELTP blog has been right and wrong

Since I began following Elite Pharmaceuticals 6 years ago I can say that there has been a lot to cheer and jeer concerning how far management has actually come.  We have seen Jerry step aside at the best possible time and the entrance of Hakim (aka Mikah).  Overall he has kept ELTP a contender in the ADT drive for market-share.  Shareholders are happy about many milestones, a hefty product pipeline, non-fluff PR, a conservative approach to an incredibly difficult sector of the market and individual product successes.  Of course that wouldn't come without speculation, broken time-windows, a long played-out FDA process, and of course years of awaiting the arrival of their star AFT formula.

In the meanwhile, in between PR and approvals, we have chat threads to gather DD from folks on chat boards with a deeper understanding of the medication development processes and other speculation on both sides of the fence.  The pumpers and the dumpers are polar opposite in their views, while most of Elite's most knowledgeable and objective posters have removed themselves from the conversation for good measure.

More than ever the speculation is doom or glory, IMO, if there's a REJECTION stamp from the FDA for Elite's ELI-200 formula, are we looking at a collapse?  With all Elite has going for them, including a recent successful Phase-3 study under the belt (The pivotal trial met its primary endpoint (p = 0.001), demonstrating statistical significance that the product provided pain relief following surgery in the treatment group using ELI-200 compared to the placebo group. Secondary endpoint results were consistent with primary findings and included safety measures. There were no serious adverse events or deaths related to ELI-200 reported during the conduct of the trial.), you would like to think the safeguards are in place.  I won't speculate much further than this, but last week's poor performance can be be blamed on various factors including China, submission waiting (for their ADT) to FDA,  or a lack of share volume.  

Major Direct Holders (Forms 3 & 4) Holder Shares Reported NIGALAYE ASHOK G 40,442,232 May 21, 2015 HAKIM NASRAT A 13,760,695 Oct 30, 2015 NARINE JEENARINE 12,262,006 Dec 31, 2015 TREPPEL JERRY 9,196,769 Nov 18, 2015 DASH BARRY H 1,084,229 Mar 5, 2015